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Abstract
At the present time, primary diagnosis of prostate cancer involves taking biopsies of the
prostate, which are proven to be very invasive and unpleasant for the patients. The ra-
diopharmaceutical [68Ga]SB3 is here presented as an alternative for diagnosing prostate
cancer through PET/CT imaging. SB3 is a bombesin analogue and a gastrin-releasing
peptide receptor (GRPR) antagonist, which highlights the potential of this tracer, since
early stage prostatic carcinomas are known for overexpressing GRPR and presenting
high affinity for bombesin analogues. Moreover, SB3 can also be labelled with 177Lu for
therapeutic purposes, which immediately suggests a theranostic approach.
The present work is based on a clinical study involving 11 patients with prostate can-
cer confined to the primary organ that underwent a PET/CT scan with [68Ga]SB3. The
goal was to estimate the dosimetry of this radiotracer, as well as its pharmacokinetic
behaviour from the application of compartmental models. It was also analysed the pos-
sibility of using [177Lu]SB3 as a therapeutic agent, along with the potential of using the
68Ga images to predict the therapy response.
Time-activity curves in multiple organs were fitted and integrated to obtain the ab-
sorbed doses. It was predicted the decay of 177Lu from the 68Ga curves for the organs at
risk and calculated the respective absorbed doses. Compartmental models were applied
to the data of 2 patients, based on activity curves of the blood, the tumour and the normal
prostate. The parameters of each model along with the concentrations in each compart-
ment allowed us to predict the tracer behaviour when labelled with 177Lu and decide if the
therapy would be favourable in each case. It was also evaluated the absorbed dose in
one of the tumours.
The highest uptake of the radiotracer was verified in the pancreas, followed by the
kidneys (pelvis) and urinary bladder, whose estimated doses were 198 µGy/MBq, 133
µGy/MBq and 115 µGy/MBq, respectively. The effective dose 103 of [68Ga]SB3 is 13
µSv/MBq. The therapeutic doses per cycle are at a maximum of 4.7 Gy, 5.5 Gy, 22.9 Gy
e 0.4 Gy for the pancreas, kidneys (cortex and pelvis) and red bone marrow assuming 7.4
GBq of administered activity. It was verified for PT2 that the specific binding of [68Ga]SB3
to the tumour was decreasing after 90 min. On the other hand, this binding seemed to
increase gradually in PT11. His tumour is expected to receive a dose of 14.1 Gy per
cycle, considering partial volume effects.
In conclusion, the effective dose of [68Ga]SB3 is similar to the effective doses of the
most common PET tracers currently used. The estimated absorbed doses in the organs
at risk do not yield significant toxicity (diagnostic and therapy). Compartmental modelling
seems to be a good method to select patients for therapy. However, it strongly relies on
the quality of the input curves. Finally, for patient 11, the estimated [177Lu]SB3 absorbed
dose may not be enough to treat the tumour, which demonstrates the importance of the
pre-treatment dosimetry.
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Resumo
Atualmente, o diagno´stico prima´rio do cancro da pro´stata envolve a realizac¸a˜o de biop-
sias da pro´stata, um me´todo que ja´ demonstrou ser bastante invasivo e desconforta´vel
para os pacientes. O radiofa´rmaco [68Ga]SB3 e´ aqui apresentado como alternativa ao
diagno´stico do cancro da pro´stata a partir de imagens de PET/CT. SB3 e´ um ana´logo
da bombesina e um antagonista dos recetores GRP. Estas caracterı´sticas realc¸am o
potencial deste fa´rmaco, dado que carcinomas prima´rios da pro´stata sa˜o conhecidos
pela presenc¸a significativa de recetores GRP e por apresentarem grande afinidade com
ana´logos da bombesina. Ale´m disso, SB3 pode ser marcado radioativamente com 177Lu
para aplicac¸o˜es terapeˆuticas, o que sugere imediatamente uma abordagem terano´stica.
Este trabalho baseia-se num estudo clı´nico que envolve 11 pacientes com cancro
da pro´stata confinado ao o´rga˜o prima´rio e que realizaram um exame de PET/CT com
[68Ga]SB3. Os objetivos foram aceder a` dosimetria e ao seu comportamento farma-
cocine´tico pela aplicac¸a˜o de modelos compartimentais. Foi ainda analisada a possibil-
idade de utilizar [177Lu]SB3 como agente terapeˆutico e o potencial de usar as imagens
de 68Ga para prever a resposta a` terapia.
O fitting e integrac¸a˜o das curvas de atividade de [68Ga]SB3 em va´rios o´rgao˜s levaram
a` obtenc¸a˜o das doses absorvidas. Foi estimado o decaimento do 177Lu a partir das cur-
vas de 68Ga nos o´rga˜os de risco e calculadas as respetivas doses absorvidas. Atrave´s
das curvas de uptake no sangue, tumor e pro´stata sauda´vel, foram aplicados modelos
compartimentais a 2 pacientes. Os paraˆmetros dos modelos e as concentrac¸o˜es em
cada compartimento permitiram prever o comportamento do fa´rmaco quando marcado
com 177Lu e decidir se a terapia seria favora´vel em cada caso. Foi estimada a dose
absorvida num tumor particular.
O paˆncreas e´ o o´rga˜o com maior captac¸a˜o do fa´rmaco, seguido pelos rins (pe´lvis) e
bexiga, cujas doses estimadas foram de 198 µGy/MBq, 133 µGy/MBq e 115 µGy/MBq,
respetivamente. A dose efetiva 103 de [68Ga]SB3 e´ de 13 µSv/MBq. As doses terapeˆuticas
por ciclo sera˜o, no ma´ximo, de 4.7 Gy, 5.5 Gy, 22.9 Gy e 0.4 Gy para o paˆncreas, rins
(co´rtex e pe´lvis) e medula o´ssea (para 7.4 GBq administrados). Verificou-se que, para
o paciente 2, a ligac¸a˜o especı´fica de [68Ga]SB3 ao tumor diminuı´a ao fim de 90 min.
Ja´ para o paciente 11, parecia aumentar progressivamente. Espera-se que o seu tumor
receba uma dose de 14.1 Gy por ciclo, considerando efeitos de volume parcial.
Em suma, [68Ga]SB3 apresenta uma dose efetiva semelhante a` dos compostos us-
ados hoje em medicina nuclear. A dose estimada para os o´rga˜os de risco (diagno´stico
e terapia) na˜o se traduz numa toxicidade significativa. A aplicac¸a˜o de modelos compar-
timentais revelou-se um bom me´todo para selecionar os pacientes para terapia, emb-
ora bastante dependente da qualidade das curvas utilizadas. Verificou-se que, para o
paciente 11, a dose absorvida pelo tumor por [177Lu]SB3 na˜o e´ suficiente para a sua
erradicac¸a˜o, o que demonstra a importaˆncia da dosimetria pre´-tratamento.
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1 Introduction
The concept of personalized medicine has been discussed in the last few years as a need
to improve therapy effectiveness and reduce side effects for the patients. Therefore,
an effort has been made among the scientific community to develop patient selection
methods for some treatments that tend to be aggressive and usually represent high costs
for the medical institutions. In Nuclear Medicine, a theranostic approach was introduced
relying on diagnostic imaging and therapy using the same or very identical molecules,
which are labelled with distinct radioisotopes or administrated in a different amount. The
idea is to visualize potential targets at first and then estimate the therapy response and
eventual toxicity.
Theranostics has proven to be a powerful strategy in cancer treatment, especially
when dealing with neuroendocrine tumours (NETs). Well-differentiated NETs overex-
press somatostatin receptors (SSTRs), whose imaging is crucial in staging, treatment
planning and follow-up of the disease. Diagnosis is accomplished with a PET/CT scan
using a somatostatin analogue (SSA) tracer labelled with 68Ga: DOTA-TATE, DOTA-TOC
or DOTA-NOC. Patients with advanced metastatic neuroendocrine neoplasia are typical
candidates for peptide receptor radionuclide therapy (PRRT) if good tumour uptake is
detected in the PET images. In a therapeutic context, it is possible to label DOTA-TATE
or DOTA-TOC with the β-emitting radionuclides 90Y or 177Lu. Since the kidneys and red
bone marrow are the most limiting organs for these therapies, 177Lu is generally preferred
over 90Y for being less nephrotoxic and hematotoxic due to its smaller range and lower
energy, allowing the PRRT to be performed in several cycles.[1] In addition, 177Lu is not a
pure beta emitter like 90Y, since it releases electrons and gamma photons during decay,
enabling treatment control through imaging techniques.
Recently, the potential of the theranostic principle has been investigated in prostate
cancer, which is globally the most common oncologic condition in men. 68Ga PET/CT
imaging with prostate-specific membrane antigen (PSMA) ligands has been established
as one of the best methods to detect prostate cancer, especially when biochemical recur-
rence of the disease is verified after radical prostatectomy or radiotherapy procedures,
since PSMA is highly expressed in poorly differentiated metastatic tumours. [2] Fur-
thermore, PSMA probes are also known for an outstanding job in diagnosing androgen-
dependent tumours with bone metastasis but have shown lower sensitivity in identifying
primary carcinomas. [3] This insight led us to conclude that radionuclide therapy using
PSMA inhibitors labelled with 177Lu might be feasible in late stages of prostate cancer.
Many studies have been performed around this topic, which is currently undergoing clini-
cal validation. One of the major concerns is the absorbed dose in normal organs like the
kidneys and salivary glands, due to tracer excretion and significant presence of PSMA
expression, respectively. [4]
At the present time, detection of prostate cancer involves, at first instance, the mea-
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surement of the level of prostate-specific antigen (PSA) in blood. High levels of this
protein are often associated to prostate carcinoma and the application of imaging tech-
niques like MRI, CT and ultrasound may posteriorly lead to an accurate diagnosis. How-
ever, these imaging procedures are usually associated with lack of diagnostic specificity.
In these cases, taking biopsies of the prostate is needed to confirm the presence of the
disease, in spite of being a very invasive and unpleasant method for the patients.
In previous studies, it was reported that primary and well-differentiated prostate can-
cer lesions also show high density expression of gastrin-releasing peptide receptors (GR-
PRs) and 50% chance of GRPR expression in androgen-dependent bone metastasis.
Therefore, targeting these receptors for tumour imaging was proposed as an alternative
for diagnosing primary and/or advanced disease stages with higher specificity and sensi-
tivity.
Sarabesin 3 (SB3) is a bombesin analogue and a GRPR antagonist. In opposition
to receptor agonists, it targets the GRPR without being internalized into the cancer cells,
preventing pharmacological effects after receptor binding and ensuring good drug toler-
ance after IV administration to the patients. It is expected that [68Ga]SB3 imaging will
provide a better diagnosis of prostate cancer in primary stages of the disease, becoming
a complement of [68Ga]PSMA, whose strength is undeniable in advanced cases. There
is also a possibility to label SB3 with 177Lu for therapy applications, which immediately
suggests a theranostic approach. [5]
In the present work, a clinical study involving 11 patients with prostate cancer was per-
formed in order to evaluate the diagnostic potential and radiation dosimetry of [68Ga]SB3,
as well as the possibility of [177Lu]SB3 administration for targeted prostate cancer therapy.
Additionally, the pharmacokinetic behaviour of the imaging tracer was investigated indi-
vidually using compartmental modelling techniques. The purpose was to inspect whether
this approach would be suitable as a patient selection method for therapy. Finally, tumour
dosimetry estimations were carried out to complement the decision process.
Apart from this introductory chapter, this dissertation features five more chapters.
The second one encounters some background information on PET, well-counter systems
and 68Ga imaging characteristics. The next two sections report some details about the
equipment, the clinical procedure and data assessment methods employed in this study.
In chapter 3, the relevant quantities in internal exposure are presented, along with the
formalism of clinical dosimetry and the mathematical fundamentals of compartmental
modelling. The forth chapter highlights the role of 177Lu in targeted radionuclide therapy,
together with some insight on how to estimate the absorbed doses to the potential organs
at risk and to the tumour from 68Ga imaging data. Chapter 5 presents the results of
the research work along with the respective discussion and the last chapter exhibits the
conclusions and perspectives on the future work.
The work for this dissertation was accomplished as a part of the master’s programme
in Medical Physics provided by the Science Faculty of the University of Porto (FCUP), in
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particular as a collaboration between the Portuguese Institute of Oncology (IPO-Porto)
and the Erasmus Medical Center in Rotterdam, the Netherlands. The internship lasted
5 months, between February and June 2019, and was supported by the Erasmus+ pro-
gramme.
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2 Image acquisition and patient data assessement
2.1 Positron emission tomography
Positron Emission Tomography (PET) is one of the tomographic imaging methods applied
in Nuclear Medicine. It relies on the administration of radiopharmaceuticals, whose struc-
ture is composed by a positron emitting radioisotope bound to a specific tracer. As soon
as the tracer targets the respective receptor, the radioisotope starts emitting positrons by
β+ decay that will interact with electrons present in body tissue, originating photons. For
each positron that results from the decay, two 511-keV photons are released in opposite
directions in a process designated by pair annihilation. The detection in coincidence of
these two photons allows image reconstruction of the activity distribution in the targeted
organs, giving access to their physiological information (figure 2.1).
In the acquisition process, the multiple detectors are organized in an array of multiple
rings around the organ of interest. Therefore, data is collected in a 360o angle around
the patient body through a process designated as Annihilation Coincidence Detection.
ACD determines that two photons are in coincidence when they fall within a specified
coincidence timing window, usually set up for 6 to 12 nanoseconds. As a result, each
photon pair is detected without using absorptive collimators in a mechanism denominated
by electronic collimation. When a coincidence event is identified, it is created a line of
response (LOR) between the two detectors that encounters the location of the annihilation
event. The simultaneous acquisition of multiple LORs allows the performance of a 3D
reconstruction and, consequently, the access to the activity distribution of the patient
slice being scanned. PET and Computed Tomography (CT) are usually combined in the
same device, as CT information is crucial to provide anatomical reference and attenuation
correction in the PET images.
Figure 2.1: Representation of the PET principle.
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PET detectors are typically composed of LSO or BGO scintillation crystals, since
these materials are not hygroscopic and have high stopping power, i.e., high density
and linear attenuation coefficient. Due to their scintillation properties, when gamma or
x-rays interact with them via photoelectric, Compton and/or pair production processes,
the crystal’s molecules are excited to higher states and return to their ground states after
the characteristic scintillation decay time of the crystal and emit light photons. These light
photons are converted into electronic pulses and amplified by the adjacent photomultiplier
(PM) tubes. Subsequently, the Pulse Height Analyzer (PHA) selects the pulses whose
amplitude coincides with the desired energy and window settings. The data is then stored
in the form of a sinogram where each LOR information is plotted in (r,φ) coordinates. For
a specific projection, adjacent detector pairs form parallel LORs for the same angle of
orientation. In short, a sinogram will represent a single slice of data for a transverse FOV
collected from a single ring of the PET device. To perform a whole-body scan of a patient,
there is a computed-monitored bedtable that moves long the axis of the detector ring.
After reconstruction, PET images can be analysed qualitatively and quantitatively. The
first relies on the observation of the radiopharmaceutical distribution and identification of
uptake regions within the human body, whereas the other encounters the determination of
radiotracer concentration based on the Standardized Uptake Value (SUV). This quantifi-
cation is performed in static images, whose analysis is the basis to accomplish dosimetric
studies.
The SUV is defined as the radiopharmaceutical concentration in tissue (ct) normalized
by the injected activity (IA) and patient body weight (BW), as presented in the following
formula:
SUV (g/ml) =
ct (MBq/mL)
IA (MBq)/BW (g)
(1)
This parameter allows activity quantification in a region of interest (ROI) independently
of the administered activity and patient body weight. However, a correction for the phys-
ical decay of the radionuclide should be applied to assess the total amount of activity
concentration in the tissue.
In equation (1), SUV can assume different forms depending on how the ROI is anal-
ysed, such as SUVmax and SUVmean. The former designation reports to the highest pixel
value within the drawn ROI, whereas the latter corresponds to a mean pixel value. For
dosimetry purposes, the SUVmean gives the most accurate estimation for the organ up-
take, as long as the ROI is faithfully placed inside the tissue region and surrounding the
hottest pixel and the organ uptake is homogeneous.
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2.2 Gallium-68 imaging characteristics
Although fluorine-18 (18F) is the standard PET radioisotope, gallium-68 is currently be-
coming more and more attractive among this field, mostly in research applications. In
practice, the first aspect that stands out is its commercial access from a germanium-68
(68Ge) generator and consequent dispensable presence of a cyclotron nearby. The half-
life of 68Ge is 270.95 days but a single clinical 68Ge/68Ga generator can only be used
during 9 to 10 months, due to quality standards for sterility and collumn decline with
acid eluates. The equilibrium between the two radioisotopes is quickly established af-
ter 68Ga elution with hydrochloric acid (HCl) to prepare several radiopharmaceuticals. It
also allows to collect information about different physiologic functions, which tend to be
more complex to image with 18F such as overexpression of somatostatin receptors and
PSMA, which are characteristic of neuroendocrine and prostatic tumours, respectively. A
simplified scheme including the decays of 68Ge and 68Ga is presented in figure 2.2.
From the physical point of view, there are some properties of 68Ga that are linked
with poorer image quality with respect to 18F. First, 68Ga disintegrates faster than 18F
(half-life of 67.71 min against 109.77 min), meaning that the time between injection and
imaging plays a significant role in the radioactivity flow from the blood to the organs. At
the same time, 68Ga manifests a lower positron yield (88.88% in opposition to 96.86% for
18F), which is translated in a lower detection sensitivity. Unlike 18F, 68Ga releases during
decay single photons with energies in the interval of 350-700 keV due to transitions from
excited states to the ground state of 68Zn with small probability, and also some scattered
photons, which contribute to the increase of image noise (figure 2.3). However, the main
gamma emission of 68Ga has an energy of 1077 keV, which falls outside the window of
the PHA included in the PET system and does not affect the image quality.
On top of that, there is quite a difference in the positron energy spectrum during the
decay of both radioisotopes. Higher end point of positron energy is verified for 68Ga
in relation to 18F (figure 2.4 (a)), which culminates in a higher distance between the
annihilation site and the position where the positron was emitted and, consequently, has
Figure 2.2: Simplified decay scheme of 68Ge and 68Ga. [6]
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Figure 2.3: Comparison between image quality in reconstructed images of the Jaszczak SPECT/PET
spatial resolution phantom with 18F (A and B) and 68Ga (C and D). Images recorded with the clinical system
Siemens Biograph 64. OSEM was employed in reconstruction. [7]
a negative impact in spatial resolution and originates partial volume effects (PVEs). In
general, the potential of recovering the true activity in 68Ga images is lower, meaning that
the measured activity is substantially underestimated. PVE is particularly relevant for
small size spheres in clinical PET, as shown in figure 2.4 (b). The recovery coefficients
(RCs) depend also on the PET scanner and are pre-calculated using phantoms with
similar characteristics (shape and size) as the volume of interest. A RC is defined as the
ratio between the activity measured in the PET image and the true activity in the phantom.
Therefore, RCs are helpful to correct the SUV or activity concentration in a certain object
without changing the image.
Surprisingly, all these drawbacks of 68Ga imaging are somehow balanced by the high
specificity and lower background activity of the uptake of 68Ga labelled agents with re-
spect to 18F labelled FDG, leading to a higher image contrast (figure 2.5).
FCUP | 8
Clinical dosimetry and pharmacokinetic modelling of
radiolabeled Sarabesin 3 with 68Ga and 177Lu
(a) (b)
Figure 2.4: (a) Energy distribution of the positron emission of 68Ga and 18F; (b) Pre-calculated recovery
coefficients as a function of object size for 18F and 68Ga in a clinical PET scanner (Siemens Biograph 64)
and respective pre-clinical scanner.[7]
Figure 2.5: Clinical FDG and [68Ga]DOTATOC PET/CT images of a patient with an unknown primary
tumour. The image on the left shows a FDG PET/CT coronal view with low specific uptake in the entire
body including the lymph node metastasis in head and neck. Other lymph node metastasis were found in
the CT images but with low FDG uptake. The primary tumour was not identified. Central and right scans
show a coronal section of the same patient imaged with [68Ga]DOTATOC one month later. Central figure
displays several lymph node metastasis with intense DOTATOC uptake, corresponding to the anatomical
changes observed in the previous FDG PET/CT scan. Right figure reveals a clearly defined and intense
lesion in the distal ileum, corresponding to the location of the primary tumour, along with multiple abdominal
metastasis.[7]
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2.3 Well-counter system
Radiation counting systems have multiple applications in Nuclear Medicine, not only in
measuring radioactivity in tissue, blood and urine samples, but also in monitoring radioac-
tive assays in radiobiology and radiochemistry. They can be composed of a single unit
controlled manually or encountered in a computer-assisted system capable of measuring
multiple samples sequentially. One of the most efficient systems for counting gamma
radiation is a well counter, commonly designated as gamma counter, with a scintillation
NaI(Tl) crystal in its constitution (figure 2.6). The crystal features a hole or well in one
end where a test tube containing the sample is placed. Well counter systems are usually
shielded with lead to reduce the amount of background counts. Moreover, the crystal
emits light that is converted in an electronic signal by an adjacent PM tube. Thus, the
working principle is identical to the one described previously for a PET ring of detectors.
However, gamma counters tend to be less efficient than PET detectors because of reflec-
tion and scattering of light in the walls of the well inside the scintillation crystal. Among
its components, there is also a high voltage supply, a preamplifier, an amplifier, single-
channel analysers (SCAs) or a multichannel analyser (MCA) to perform PHA, a digital
or analogue scaler-timer and a rate meter that converts the pulses in counts per minute
(cpm) or counts per second (cps).
Gamma counters require periodical calibration to ensure that the PHA discriminators
match directly the pulse height with the respective energy of the gamma energy mea-
sured. This procedure is designated by high-voltage or energy calibration and is accom-
Figure 2.6: (A) Scheme of a well-counter’s cross-section containing a test tube with a radioactive sample;
(B) Manually operated well-counter with a digital readout and a printer (Capitec Inc., Ramsey, NJ).[8]
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plished by inserting a 137Cs source in the well. 137Cs has a characteristic emission at 662
keV. Therefore, the lower and upper limits of the PHA are established at 640 and 684 di-
visions, respectively, so that the centre of the photopeak would fall at 622 divisions which
is associated with the 662-keV gamma photons. The calibration process involves calibra-
tion of the count rate against a known activity, preferrably a standard activity, compared
to some primary standard provided by a metrology institute.
In the interest of quantifying the absolute activity of a radioactive sample, it is impor-
tant to evaluate the detection efficiency of the gamma counter for the desired gamma
energy using a standard radioactive sample of known activity. The efficiency of the pho-
topeak is given by the ratio between the count rate of the standard radioactive source
obtained with the adequate PHA configuration and the disintegration rate associated to
the known activity of that standard source and should be estimated for each photon en-
ergy, so that the efficiency correction could be applied to the count rates of sample with
unknown radioactivity.
A given radioactive sample can release multiple gamma rays due to the presence of
single or multiple radionuclides, which yields a more complex energy spectrum, since
there is superposition of the multiple photopeaks, as well as formation of spillover or
crosstalk contributions from Compton interactions of the high-energy photons with the
lower-energy photopeaks. As a result, corrections in the energy distribution should also
be applied regarding this type of phenomena.
Sample volume is also a factor that affects the counter efficiency. The bigger the sam-
ple volume with a given activity, the lower is the detector efficiency, since a larger number
of photons escape from the well without interacting with the crystal. In general, detection
efficiency of a gamma counter decreases when the photon energy is increased and/or
detector size is reduced. Maximum detection efficiency for a given volume, activity and
detector size is achieved when the sample is placed in the center of the well.
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2.4 Equipment
The PET/CT scanner used in this clinical study was the Siemens Biograph mCT (Siemens,
Erlangen, Germany) shown in figure 2.7, whose camera is calibrated according to the
EARL protocol integrated in the european guidelines. [2] The encountered software ver-
sion is the syngo MI.PET/CT 2012A. PET detectors are distributed in 4 rings with 48
detector blocks in each one. Each detector ring has a diameter of 84.2 cm. LSO crystals
with size 4x4x20 mm are arranged in a 13x13 array coupled to a 2x2 PM tube array in
each detector block. This configuration provides an axial PET field of view (FOV) of 22.1
cm and a transaxial FOV of 70 cm. The coincidence time window is 4.1 ns and the device
offers time-of-flight performance that results in a system time resolution of 540 ps. The
energy window is set up in the range of 435-659 keV. An integrated 64 or 128-slice CT
is used for attenuation correction of PET data. Tube voltage options of 70, 80, 100, 120
and 140 kV are offered for CT acquisition. Lastly, it has a tunnel length of 136 cm and the
table supports a maximum weight of 227 kg.[9]
Figure 2.7: Siemens Biograph mCT PET/CT scanner (Siemens, Erlangen, Germany).[9]
In order to quantify the activity in blood and urine samples, it was used the Perkin
Elmer WIZARD 1480 automatic gamma counter (Perkin Elmer, Massachusetts, USA)
presented in figure 2.8.[10] This equipment includes one NaI(Tl) detector shielded with
75 mm of lead and allows the measurement of 1000 samples in 13 mm diameter tubes or
270 samples in 28 mm tubes at the same time. The placement of the samples inside the
well is assisted by an unique arm. According to the manufacturer, it is ideal to perform
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measurements of high energy gamma emitters and low activity samples. Moreover, this
device provides a high resolution MCA with 1024 channels and performes automatic
corrections for the background counts and efficiency.
Figure 2.8: Perkin Elmer WIZARD 1480 automatic gamma counter (Perkin Elmer, Massachusetts,
USA).[10]
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2.5 Clinical procedure and data assessment
The PET/CT acquisition study protocol for [68Ga]SB3 uptake in early stage prostate can-
cer patients consisted in the following proceedings:
1. dynamic list mode acquisition for 20 minutes from immediately before injection;
2. acquisition of single bed static PET images of the pelvic area at 30 and 45 minutes
post injection, 6 minutes per bed position (mbp);
3. acquisition of single bed static images of upper abdomen at 36 and 51 minutes (6
mbp);
4. acquisition of whole-body images (from crown of head to lower thigh) at 60 and 120
minutes using 7 bed positions (4 mbp except for pelvic area, which were 6 mpb);
5. acquisition of single bed static images of the pelvic area at 150 and 210 minutes
(12 mbp);
6. acquisition of single bed static PET images of upper abdomen at 170 minutes (12
mbp).
All PET acquisitions were preceded by a low dose CT scan using 120 kVp and 40 ref
mAs for the static PET scans or 120kVp and 20 ref mAs for the whole-body PET scans.
The administrated activities of [68Ga]SB3 and body weight values are presented in table
2.1 for each patient.
PET image reconstruction was performed with an ordered subset expectation maxi-
mization (OSEM) algorithm using resolution recovery, time-of-flight information, 3 itera-
tions, 21 subsets and a 3 mm post-reconstruction Gaussian filter. Attenuation and scat-
tering corrections were also applied during reconstruction.
Patient number Administered activity (MBq) Body weight (kg)
1 159 83
2 155 92
3 130 88
4 247 92
5 210 82
6 159 100
7 150 88
9 260 90
10 210 69
11 206 82
12 158 87
Table 2.1: Individual administered activities of [68Ga]SB3 and patient body weights in MBq and kg,
respectively.
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Regarding image measurements, volumes-of-interest (VOI) were drawn on the PET/CT
fusion images using OsiriX 5.9 (Pixmeo Sa`rl, Bernex, Switzerland). Quantification of
uptake, was expressed by the SUV and corrected for injected dose, body weight and
radioactive decay.
It should be noted that the acquisition procedure mentioned in this section took place
in 2017. Therefore, the data analysis presented in this dissertation was based in SUV
measurements and blood and urine activity counts that were previously collected.
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3 Clinical dosimetry and pharmacokinetic modelling
3.1 Dosimetric quantities in internal exposure
In Nuclear Medicine, it is of extreme importance the quantification of internal exposure
from radionuclides, especially in therapeutic procedures. In diagnostic applications, some-
times the high doses are justified if they lead to a well funded diagnosis. Either way, the
fundamental dose quantity is the mean organ or tissue absorbed dose DT , which is de-
fined as the ratio between the total energy imparted by ionising radiation T to organ
or tissue T and its mass mT , as showed in equation (2). It is expressed in joules per
kilogram (J/kg) in SI units, which is equivalent to gray (Gy).
DT =
T
mT
(2)
However, it is common knowledge in radiobiology that different types of ionising radi-
ation cause different degrees of damage in a given organ for the same delivered dose.
For instance, alpha particles and neutrons are more harmful for a certain tissue, when
exposed to the same dose, than gamma rays or electrons , due to their higher capability
of producing irreversible damage by dense ionisation phenomena. In order to include
this evidence, a new definition of dose was introduced. The equivalent dose HT is the
multiplication of the organ absorbed dose by a radiation weighting factor wR that consid-
ers the biological effect of the type of radiation delivered to that organ, as displayed in
equation (3). Thus, DT,R becomes the mean absorbed dose in an organ or tissue by type
R radiation.
HT = wRDT,R (3)
Equivalent dose is also expressed in joule per kilogram (J/kg), but in this case it corre-
sponds to a sievert (Sv). The values of weighting factors wR for each type of radiation
are shown in table 3.1 according to the ICRP Publication 60 but they were posteriourly
updated on the ICRP Publication 103 (table 3.2). All values correspond to radiation either
incident in the body or emitted internaly from radionuclides. The total equivalent dose in
a tissue is given by the sum of the equivalent doses for each type radiation present in an
exposure procedure.
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Radiation type Radiation weighting factor wR
Photons, electrons and muons 1
Protons, other than recoil protons
Energy > 2 MeV
5
Alpha particles, fission fragments
and heavy ions
20
Neutrons
Energy < 10 keV 5
10 keV to 100 keV 10
> 100 keV to 2 MeV 20
> 2 MeV to 20 MeV 10
> 20 MeV 5
Table 3.1: Weighting factors wR for each type of radiation according to ICRP Publication 60. [11]
Radiation type Radiation weighting factor wR
Photons, electrons and muons 1
Protons and charged pions 2
Alpha particles, fission fragments
and heavy ions
20
Neutrons
En < 1 MeV 2.5 + 18.2e−[ln(En)]
2/6
1 MeV ≤ En ≤ 50 MeV 5.0 + 17.0e−[ln(2En)]2/6
En > 50 MeV 2.5 + 3.25e−[ln(0.04En)]
2/6
Table 3.2: Weighting factors wR for each type of radiation according to ICRP Publication 103. For neutrons,
the factor depends on the their energy En.[12]
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The effects of radiation exposure at a cellular level can be split into two groups. The
first one incorporates deterministic effects, which reflect themselves in malfunction of
cells after exposure to high doses of radiation, and the second one includes stochastic ef-
fects, which are related to cancer and hereditary disorders induced by radiation exposure
at low doses. Stochastic effects have a certain probability of being induced depending
on the type of organ or tissue being irradiated. To account this factor, a quantity denom-
inated as effective dose E was presented in ICRP Publication 60 as a weighted sum of
the tissue equivalent doses
E =
∑
T
wTHT (4)
where wT is the tissue weighting factor for tissue T. The wT factors represent the con-
tribution of each tissue of the human body, in which there is a probability of inducing
stochastic effects, to the overall radiation dose. The SI unit for effective dose is joule per
kilogram (J/kg), also denominated as sievert (Sv) like for the equivalent dose.
In practice, it is not possible to measure equivalent dose or effective dose. The dose
coefficients relative to the internal exposure from radionuclides are estimated using bioki-
netic models, reference physiological data or computational phantoms. At the present
time, computational phantoms of the adult Reference Male and adult Reference Female
are employed, whose organs are designed to match the organ masses defined for a refer-
ence adult in ICRP Publication 89. [13] Significant anatomical differences between male
and female adults led to the definition of a new effective dose, in which tissue weighting
factors are sex- and age-averaged for all organs and tissues, also involving male and
female breast, testis and ovaries. Thus, according to ICRP Publication 103, the effective
dose is determined from the equivalent doses of each organ or tissue T of the Reference
Male (HTM ) and of the Reference Female (H
T
F ) as in following formula
E =
∑
T
wT
[
HTM +H
T
F
2
]
(5)
Recent and old tissue weighting factors wT are displayed in tables 3.3 and 3.4. In
the recent table, the remainder includes 13 different tissues: adrenals, extrathoracic (ET)
region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas,
prostate (for male), small intestine, spleen, thymus, uterus/cervix (for female).Therefore,
the equivalent doses to remainder tissues of the Reference Male (HMrmd) and Reference
Female (HFrmd) are given by
HMrmd =
1
13
13∑
T
HTM H
F
rmd =
1
13
13∑
T
HTF (6)
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Tissue Tissue weighting factors wT
Bone surfaces 0.01
Bladder 0.05
Breast 0.05
Colon 0.12
Gonads 0.20
Liver 0.05
Lungs 0.12
Oesophagus 0.05
Red bone marrow 0.12
Skin 0.01
Stomach 0.12
Thyroid 0.05
Remainder 0.05
TOTAL 1.00
Table 3.3: Tissue weighting factors wT according to ICRP Publication 60. [11]
Tissue wT
∑
wT
Red bone marrow, Colon, Lung,
Stomach, Breast and Remainder 0.12 0.72
Gonads 0.08 0.08
Bladder, Oesophagus, Liver,
Thyroid
0.04 0.16
Bone surface, Brain, Salivary
Glands, Skin
0.01 0.04
TOTAL 1.00
Table 3.4: Tissue weighting factors wT according to ICRP Publication 103. [12]
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Figure 3.1 explains schematically how to obtain the sex-averaged effective dose, com-
monly designated as effective dose 103. This quantity only takes into account the expo-
sure conditions and the tissue weighting factors are mean values estimated from many
individuals of both sexes.
Figure 3.1: Calculation steps to obtain the effective dose 103.[12]
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3.2 Dosimetry formulation
Part of the Society of Nuclear Medicine, the Committee on Medical Internal Radiation
Dose (MIRD) made an effort to unify the methods and notation employed in internal
dosimetry calculations along with the International Commission on Radiological Protec-
tion (ICRP), which culminated in the publication of the MIRD Pamplet No. 21 [14, 15].
According to this latest formalism, the absorbed dose D to a target region rT due to
the activity in a source region rS is obtained by the following relation between the time-
integrated activity A˜ and the S-value
D(rT ) = A˜(rS) · S(rT → rS) (7)
Absorbed dose values are expressed in joule per kilogram (J/kg) in SI units, which com-
monly known as gray (Gy).
The S-value represents the absorbed dose rate per unit activity in Gy · (Bq · s)−1
and its definition is presented in equation (8). It depends not only on the energy emitted
by the radionuclide (E) and the probability Y of that emission, but also on the absorbed
fraction φ and the mass of the target regionM(rT ). The absorbed fraction φ is denoted as
the fraction of energy emitted by the source region that is absorbed in the target region,
i.e., it is a value between 0 and 1. Many factors influence this later quantity such as
the shape, size and mass of the source and target regions, as well as the distance and
type of material between the source and the target regions, and also the type of radiation
emitted by the source and its energy. Therefore, all these aspects also have an impact
on the S-value.
S =
EY φ
M(rT )
(8)
S-values for a given radionuclide and source-target arrangement are generated from
Monte Carlo simulations using anatomical phantoms.
The time-integrated activity A˜(rS) indicates the number of desintegrations that occur
in a specific source region in Bq · s. This latter quantity is usually calculated as the area
under the time-activity curve on the source region after the injection of the radiotracer,
i.e., can be calculated as the integration of the activity of the source region A(rS , t) over
a period TD
A˜(rS , TD) =
∫ TD
0
A(rS , t)dt (9)
The integration period TD is often chosen from the time of injection of the radiotracer
(t = 0) until infinity (t =∞), since the radionuclides used in nuclear medicine procedures
have relatively short physical half-lives.
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The time-integrated acitivity coefficient of the source region a˜(rS) (TIAC), which is a
new designation for the residence time [14], is also an important quantity on dosimetry
studies. It is expressed in units of time and defined by
a˜(rS) =
A˜(rS)
A0
(10)
where A0 is the radiopharmaceutical administered activity. It is interpreted as an average
time that the radioactivity spends in a source region.
The activity in the target region as a function of time A(rS , t) is usually characterised
by a sum of exponential functions as presented in equation (11). For all j exponentials, Aj
denotes the respective initial activity, λp the physical decay constant of the radioisotope,
λj the biological decay constant and t the time after the injection of the radiotracer.
A(rS , t) =
∑
j
Aj · e−t(λp+λj) (11)
Each decay constant λ is related with its respective half-life T1/2 as presented in equation
(12). The physical half-life T1/2,p and the biological half-life T1/2,j can be incoporated in
an effective half-life T1/2,eff as in equation (13), which is always shorter than the physical
and biological half-lives apart.
λ =
ln(2)
T1/2
(12)
1
T1/2,eff
=
1
T1/2,p
+
1
T1/2,j
(13)
Combining equations (9) and (11), it is clear that the time-integrated activity A˜(rS)
when the activity of a source region A(rS , t) is described by a single exponential curve is
A˜(rS) =
∫ ∞
0
A(rS , 0) · e−t(λp+λj) = A(rS , 0)
λp + λj
(14)
Other integration methods can be employed like trapezoidal or Riemann integration,
depending on how well the time-acitivity curve is fitted. A representation of the three
integration methods is shown in figure 3.2. In order to achieve a reasonable fitting, at least
three data points per exponential phase are required and the data should be recorded
along two to three effective half-lives of the radionuclide in question (at minimum).
Finally, according to the bladder model elaborated in the MIRD Pamphlet No. 14 [16],
it is possible to estimate the time-integrated activity coefficient a˜(rS) of the urinary bladder
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wall due to the radioactivity clearance through the urine as presented in the following
equation
a˜(rS) =
∑
j
αj
[
1− eλpTν
λp
− 1− e
(λp+λj)Tν
λp + λj
]
×
[
1
1− e(λp+λj)Tν
]
(15)
where αj stands for the biologic coefficients representing the fraction of the administered
activity entering the bladder for the jth component, λj is the biologic rate constant for
entry of the jth component into the bladder and Tν is the voiding time interval.
Figure 3.2: Different ways of calculation the time-integrated activity: (a) fitting the curve with an exponential
function; (b) trapezoidal integration; (c) Riemann integration.[15]
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3.3 Compartmental modelling
Compartmental modelling is a mathematical strategy to examine dynamic PET data that
allows the characterization of the radiopharmaceutical’s kinetics and prediction of its inter-
action with the different tissues. This concept relies on separating the different physiolog-
ical states of the tracer into different compartments that interact with each other through
transfer rates. The first compartment of every model represents the arterial blood and
the number of compartments added to the model depends on the chemical and biological
properties of the radiotracer.[17] The simplest model encounters a one-tissue compart-
ment (figure 3.3) and the exchange between the two compartments is characterized by
two rate constants K1 (in ml · g−1 ·min−1) and k2 (in min−1), which describe the uptake
and clearance of the pharmacon.
Figure 3.3: One-tissue compartment model.[18]
The concentration of the tracer in the tissue (C1) can be assessed by solving the
following differential equation
dC1(t)
dt
= K1CP (t)− k2C1(t) (16)
where CP is the concentration of the tracer in the arterial plasma. In this model, the
concentration in the tissue represents the free and non-specific binding of the tracer, i.e.,
the perfusion of the tissue. The model curve is given by
Cmodel(t) = (1− νB)C1(t) + νBCB(t) (17)
where νB is the blood volume fraction and CB(t) the concentration of the tracer in the
whole blood.
The kinetics of some radioligands matches with a two-tissue compartmental model
(figure 3.4), which includes an extra compartment that represents the specific binding of
the tracer and whose concentration is C2. The exchange between tissue compartments
is expressed by the rate constants k3 and k4, both in min−1. Tissue concentrations C1
and C2 are associated with two differential equations (18, 19).
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Figure 3.4: Two-tissue compartment model.[18]
dC1(t)
dt
= K1CP (t)− (k2 + k3)C1(t) + k4C2(t) (18)
dC2(t)
dt
= k3C1(t)− k4C2(t) (19)
The model curve is given by
Cmodel(t) = (1− νB)(C1(t) + C2(t)) + νBCB(t) (20)
Therefore, it is possible to solve the differential equations associated to the model
based on the activity curves of the arterial plasma and of the tissue over time and, conse-
quently, reach the concentrations in each compartment together with the rate constants
that characterize compartment exchange. These parameters describe quantitatively the
pharmacokinetics of the tracer.
It is worth noting that the equations associated to the compartmental models pre-
sented in this section are only valid when the physical decay constant of the radioisotope
in question is negligible when compared to the biological decay constant of the same
radioisotope in the tissue being analysed.
Biokinetic models and data of different radiopharmaceuticals have been reported in
several publications of the ICRP over the years, being the ICRP Publication 128 the most
recent one related to this topic. [19]
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3.4 Software
In spite of using Microsoft Excel, Office 365 (Microsoft, Washington, USA) to organize the
data and perform intermediate calculations, some specific software was also employed,
whose characteristics are described in the following paragraphs. The software’s interface
is shown in the subsequent methodology sections.
GraphPad Prism 5 (Graphpad Software LLC, San Diego, USA) is a software devel-
oped for data analysis, providing a myriad of statistical methods for this purpose. Besides
organising the data in tables and plotting the respective graphs, it allows curve fitting by
linear and non-linear methods with multiple functions as options. It also offers the possibil-
ity of comparing differents fits by Akaike information criteria or an F-test, to decide which
one mimics better the data behaviour. The parameters of the fittings are displayed along
with their absolute errors and their 95% confidence intervals. Additionally, it provides
multiple routines to evaluate whether a sample follows a normal probability distribution or
not. This software was employed to perform the fitting of the SUV/BW curves and the
correspondent fitting parameters allowed the estimation of the TIAC of each organ.
IDAC Dose 2.1. [20] is a program created in 2017 to perform internal dosimetry
calculations according to the ICRP-specific absorbed fractions and using the organ of
a reference adult as described in ICRP Publication 133 [21]. The software allows the
estimation of the organ absorbed doses, as well as the effective doses as described in
ICRP Publications 60 and 103 [11, 12], after inserting each organ TIAC as input. The
calculation is suported by the radionuclide decay database of ICRP Publication 107 and
takes into account 83 different source regions which irradiate 47 target tissues. It also
provides an option for calculation of the absorbed dose in spheres with different volumes
and composition, which is helpful in radionuclide therapy dosimetry.
OLINDA/EXM 1.0 [22] is also an internal dosimetry computer program, but developed
before IDAC DOSE 2.1. The interest of this software for the present work relies on the
incorporation of a bladder model that allows the estimation of the bladder’s absorbed
dose, in a given voiding interval, from the estimated TIAC based on the radioactivity
uptake in the urine.
PMOD 4.004 (trial version), PKIN module (PMOD Technologies LL, Zurich, Switzer-
land) [18] was designed for the simulation and fitting of compartment models applied
to PET and SPECT data. Time-activity data of the blood plasma and of a given tissue
are imported to the program in text file configuration. As an initial aproach, the software
fits the time-activity curves and uses them to solve the differential equations associated
to the compartment model selected. There are displayed plots with the TACs, the be-
haviour of the concentration in each compartment and of the total concentration of the
model. These results along with the model parameters enable the access to the kinetic
behaviour of the radiotracer analysed.
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3.5 Dose quantification
As an initial approach, mean SUV values of each organ collected from static PET im-
ages were corrected for patient body weight and the SUV/BW curves were fitted in the
Prism software assuming a least squares ordinary fit. Data points outside the range of
three standard deviations from the mean values were excluded and considered as out-
liers according to the outlier rule of thumb. [23] Single exponential curves with or without
a residual were compared by Akaike information criteria whenever possible, and alterna-
tively with an extra sum-of-squares F-test with p = 0.05, to inspect which function better
described the uptake in each organ. [24] The time-SUV/BW curves were plotted along
with their best fitting models and their correspondent 95% confidence intervals.
With the aim of obtaining the TIAC for each organ, the SUV/BW curves were inte-
grated in time from 0 to ∞, after applying the correction for the physical decay of 68Ga.
From this operation, TIAC in h/ml were reached and then multiplied by the target masses
of the organs in g given in IDAC Dose 2.1. to convert them in h. This operation is allowed
because the software assumes that all the organs are composed of water surrogate tis-
sue, i.e., their masses in g correspond to their volumes in ml. Finally, the TIAC in h were
used as input in the main menu of IDAC (figure 3.5) to obtain the absorbed doses to the
target organs expressed in mGy/MBq as well as the overall effective doses 60 and 103.
Urine activity information was analysed as the cumulative percentage of the injected
activity behaviour over time in min. The data points were fitted according to a single
exponential cumulative function, i.e., of the type f(t) = A + B · (1 − e−λt), where A and
B are constants. The TIAC of the urinary bladder was calculated using the MIRD bladder
voiding model (15), assuming only one component (j = 1) since the activity behaviour
was described by a single exponential growth. The parameter α1 was estimated using the
constants A and B from the fitting. The bladder TIAC in h was estimated for voiding time
intervals Tν of 0.5h and 1h. A correction factor of 0.01 was applied in the α1 parameter,
since it needed to fall between 0 and 1.
Lastly, the TIAC of the bladder was also calculated in OLINDA/EXM 1.0., to verify the
result previously obtained. This software includes the same voiding bladder model in its
interface and its filling requirements are the parameters α1, Tν and the half-life of the
activity being cleared through the urine expressed in h (figure 3.6).
Along the dosimetry process, it was necessary to match the different organs with the
source organs and target masses provided by IDAC. This correspondence is illustrated
in table 3.5, along with an explanation about how the overall time-activity coefficients
of some organs were obtained from the values of their different parts. For most of the
organs, the TIAC was calculated taking into account one SUV measurement in the image
(1 value). The other TIACs resulted from multiple measurements of SUV in different parts
(2 or 3) of the organ in question, being the overall result obtained as the average or the
sum of the TIACs associated to the individual parts. The target masses of all irradiated
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Figure 3.5: IDAC Dose 2.1. interface to insert the TIACs of each organ in h and, consequently, calculate the
organ absorbed doses and effective doses for the radionuclide chosen.[20]
Figure 3.6: OLINDA/EXM 1.0 interface of the voiding bladder model. [22]
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organs provided by IDAC is in figure 3.7. It is important to note that the data collected from
the blood was treated as uptake in the red bone marrow when using IDAC to calculate the
absorbed dose. This procedure is always valid when we are dealing with small molecules
and the red bone marrow is expected to experience very low specific uptake. [25] Values
from the first time point (t = 0 min) were excluded from the fitting because they were
identified as measurements of the background counts.
On this study, SUV values of the nipple, oesophagus (low tract) and rectalfincters
were not analysed, as it was not possible to find analogous input in the IDAC interface.
These organs were not expected to have a significant uptake, so their omission would not
have a relevant impact on the final absorbed dose values.
As a complement, the uncertainty associated with these dosimetry calculations was
quantified by the standard error associated to the determined TIAC. Depending on the
fitting needed to deduce the TIAC of each organ, the standard error (SE) was estimated
as follows
SE(a˜) = a˜ ·
√√√√ n∑
i=1
(σK
K
)2
(21)
where n is the number of independent parameters needed to calculate a˜, K is the value
of each parameter and σK is its respective standard error. This is a simplication of the
covariance matrix, which also takes into account any cross-over influence between pa-
rameters on the uncertainty. The individual standard error values are estimated by Prism
when the fitting is performed.
In the individual dosimetry analysis, the same method reported previously was em-
ployed individually to obtain the fittings for the organs which provided more than two data
points. Trapezoidal integration was applied to the data which showed a poor R2 and for
the organs that had only two data points. Therefore, the overall time-activity coefficients
introduced in IDAC to obtain the absorbed doses were a combination of trapezoidal inte-
gration and fitting results.
Individual urinary bladder TIACs were assessed by the same process for 1h voiding.
Regarding the red bone marrow dose, the TIACs used in IDAC came from the PET image
measurements. It is important to mention that PT7 was excluded in this part of the study,
since it was verified he was under prostate medication that would interfere in the dose
results.
It must be pointed out that the effective dose estimated using the methods of this
section corresponds only to the PET scan. Therefore, there is an additional contribution
of dose delivered during the CT scan, which is expected to be around 18 mSv according
to the RADAR Medical Procedure Radiation Dose Calculator and assuming a helical CT
scan of the chest, abdomen and pelvis. [26]
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Organs Overall calculation of TIAC IDAC volume match IDAC dose input
Heart 1 value Heart wall
Blood (A, P)1 Average Red (active) bone marrow
Muscle (A, P) Average Muscle
Bone (A, P) Average Endosteum
38% Cortical bone surface
62% Trabecular bone surface
Pancreas
(head, mid, tail)
Average Pancreas
Kidneys (R, L) 2 Sum Kidneys
Pyelum (R) 1 value Ureters
Lung 1 value Lungs
Thyroid 1 value Thyroid
Liver 1 value Liver
Spleen 1 value Spleen
Oesophagus
(high, mid)
Average Oesophagus
Stomach 1 value Stomach wall
Intestine 1 value Small intestine wall
Colon Same value for Left/Right Colon
Left colon wall
Right colon wall
Rectum 1 value Recto-sigmoid colon wall
Prostate 1 value Prostate
Urine 1 value ——————— Urinary bladder contents
Table 3.5: Target organs and respective IDAC volumes and dose inputs.
1Abdominal and pelvic measurements
2Right, Left
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Figure 3.7: Target masses of all possible irradiated organs provided IDAC. [20]
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3.6 Pharmacokinetic analysis
The pharmacokinetic analysis with the application of compartmental modelling is based
on the time-activity curve of the arterial plasma, also designated as Arterial Input Function
(AIF), and on the time-activity curve of a given tissue, both including dynamic and static
data. This analysis was performed only for patients 2 and 11 individually, since the AIFs
of the other patients were strongly scattered at early time points and, when inserted in the
PMOD software, led to inconclusive results when estimating the compartimental curve’s
behaviour and respective parameters.
In the first place, to import the time-activity curves of the plasma and the tissue into
PMOD, the user manual establishes that this information should be presented in a text
file, with the time points in seconds and the activity points in kBq/cc (kilobecquerel per
cubic centimeter). Since the activity is first expressed by the SUV, a conversion to kBq/cc
was required, which involved using the actual injected activity and body weight of the
patient being analysed, according to equation (1).
The remainder steps were the simplest, due to the user-friendly interface of PMOD
PKIN module (figure 3.8). On bottom left corner of the window, there is the ”kinetic” with
options to import the text files with the activity data from both plasma and tissue. On
the top right corner of the window, we can select the compartment model to perform
the fitting. The parameters of the model appear right below, along with the respective
standard error. Two graphs of strong relevance are also displayed. The first one on the
top left corner includes both activity curves (plasma and tissue) together with the model
curve (Cmodel). The other one on the bottom right corner presents the behaviour of the
concentration in the tissue compartments also with the model curve (Cmodel). There is
the option of showing other behaviours in the graphs, but the ones described here were
thought to be the most important.
Another point worth noting is that, in this situation, the tissue is either the tumour or
the normal prostate. A two-tissue compartment model was applied for the tumour of both
patients and for the normal prostate tissue for patient 11. This healthy tissue was also
examined using a one-tissue compartment model for comparison purposes.
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Figure 3.8: PMOD PKIN module interface. [18]
FCUP | 33
Clinical dosimetry and pharmacokinetic modelling of
radiolabeled Sarabesin 3 with 68Ga and 177Lu
4 Radionuclide therapy
4.1 Lutetium-177 in targeted radionuclide therapy
Lutetium-177 (177Lu) decays 100% by β− emission, but it is not a pure beta emitter ac-
cording to the decay scheme shown in figure 4.1. Most of the disintegrations of this ra-
dionuclide (79.3%) are into stable isotopes of hafnium-177 (177Hf) with a half-life of 6.647
days, followed by less frequent decay events for excited states. Subsequent de-excitation
for the ground state of 177Hf is accompanied by photon emission. Thus, in the radioactive
decay of 177Lu, the main particle emission events are of β− particles with energies 498
keV, 385 keV and 177 keV, as well as low-energy gamma photons of 113 keV and 208
keV.
There are many characteristics of 177Lu that explain the increasing application of this
radioisotope in targeted radionuclide therapy. In the first place, the electrons released dur-
ing decay (including Auger electrons) experience a mean penetration range of 670 µm in
soft tissue, which allows the erradication of small tumours or metastasis while sparing the
surrounding normal tissues. At the same time, the low-energy gamma photons emitted
enable treatment control through imaging techniques, as well as dosimetric and kinetic
studies before and during treatment, which contributes for a personalized medicine ap-
proach. Since the beta particles and the photons emitted are of average and low energy,
respectively, they are associated to relatively low levels of radiation, which simplifies the
labelling process to obtain the radiopharmaceuticals and their administration to the pa-
Figure 4.1: Decay scheme of 177Lu. [6]
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tients. In a chemical point of view, there is labelling compatibility with several molecules,
including peptides, proteins and antibodies depending on the target organ. As it is a
longer-lived radionuclide, 177Lu demonstrated to be particularly suitable for antibody la-
belling, since these molecules tend to demonstrate slower kinetic properties. At last
instance, its longer half-life contributes to reduce activity losses during transportation be-
tween production and medical facilities, as well as between the storage and the patients’
rooms for further injection.
The production of 177Lu for medical applications involves a nuclear reactor and can
be performed by two different methods (figure 4.2). The direct method requires neutron
irradiation of 176Lu targets, in which 177Lu is created along with photon emission. The
second production method is indirect and relies, in the first place, on neutron irradiation
of ytterbium-176 (176Yb) targets, producing 177Yb that experiences β− decay into 177Lu. At
this point, a chemical separation procedure is needed to remove the 176Yb target atoms.
The advantage of this carrier-free route is that it yields higher specific activities and no
production of 177mLu.
After obtaining the radioisotopes and before the preparation of the desired radiophar-
maceuticals, quality control operations take place to evaluate 177Lu purity, a property that
has a large influence on its specific activity. In a particular application, the number of
target receptors determines the amount of 177Lu specific activity that is needed to be in-
corporated in the radiotracer. At this point, many 177Lu radioagents have been produced
and analysed to be applied in several terapeutic procedings such as peptide receptor ra-
dionuclide therapy, bone pain palliation, radiation synovectomy and radioimmunotherapy.
Figure 4.2: Methods employed in reactor production of 177Lu.[27]
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4.2 Normal organ dosimetry
It was already recognized that the potential organs at risk in imaging with a GRPR an-
tagonist are the pancreas and the kidneys. In therapeutic circumstances, quantifying the
dose delivered to the red bone marrow is also of strong importance to avoid future per-
manent damage. Therefore, the possibility of using [177Lu]SB3 as a therapy agent was
evaluated, estimating its absorbed dose to the pancreas, kidneys and red bone marrow
based on the obtained decay of [68Ga]SB3 in these organs.
In first instance, the biological half-life of [177Lu]SB3 was assumed to be equal to the
biological half-life of [68Ga]SB3. Subsequently, it was estimated the effective decay con-
stant of [177Lu]SB3 in the pancreas, keeping in mind equations (12) and (13) and the
same analysis performed by Gnesin et al. [28] The TIAC in h/ml was obtained, consid-
ering that the SUV/BW curve in time for the pancreas follows a single exponential decay
without residual. TIACs and respective absorbed doses (in Gy/GBq) were obtained for
each patient pancreatic volume, as well as for the average and phantom pancreas vol-
umes.
It was possible to estimate the individual volumes of the pancreas from the PET im-
ages. Moreover, IDAC provides a S-value for an adult male standard pancreas volume
after selecting a pancreas TIAC of 1h in the main menu. This S-value allows to make a
prediction on the S-value for each individual pancreas volume assuming a linear relation
between these quantities. Finally, absorbed doses to the pancreas were also quantified
for an administered activity of 7.4 GBq, which is the typical activity amount injected in
prostate cancer therapy with other 177Lu radiolabelled agents.
The evaluation of the [177Lu]SB3 absorbed dose to the kidneys relies on the same cal-
culation method as for the pancreas. However, some different aspects should be noted.
In this case, the TIAC in h/ml was estimated for each kidney part involved, i.e., right and
left kidney cortexes and right pyelum (kidney pelvis). Cortex TIAC values were added
and multiplied by the volume in ml of both kidneys in the reference male phantom. As
mentioned in table 3.5, the pyelum was treated as an ureters surrogate, so its TIAC was
determined using the reference male ureters volume in ml.
The absorbed dose to the red bone marrow was assessed in the same way but only
for the respective reference volume in the male phantom. The fitting parameters of the
blood sample curve were used in this case, since they are expected to give more accurate
results and to provide a higher TIAC, which would result in a higher absorbed dose.
Quantifying this systematic error involved the 95% confidence intervals associated to
the Prism fitting parameters for these organs. The calculation is performed in the same
as described earlier in this section but using the upper and lower limits of the 95% con-
fidence intervals of the biological decay constant of the organ to obtain the absorbed
doses. It should be pointed out that the biological decay constant and the correspondent
absorbed dose are inversely related, i.e. the lower limit of the 95% confidence interval
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corresponds to a higher dose and vice-versa. In the end, it was possible to determine an
extra dose range that would remain in each target organ.
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4.3 Tumour and normal prostate dosimetry
In this section, a review on the methodology used to estimate the 177Lu absorbed dose
to a particular tumour is presented. First of all, the tumour SUV/BW curve, including
dynamic and static data, was fitted in Prism. A function of the type f(t) = A·(e−λ1t−e−λ2t)
(A is a constant) was found to be the most suitable to mimic the data behaviour, which is
typical of an uptake and excretion curve. In the fitting parameters, there was an estimation
of the biological half-life of the tumour and, together with the physical half-life of 177Lu, a
quantification of the tumour’s TIAC in h/ml was achieved.
In a situation in which the measurement of tumour volume is not possible, it can be
created a range of volumes, whose upper limit is the volume of the prostate in the male
phantom. Those volumes are required to obtained the TIACs in h. Hereafter, it was
calculated the time-integrated activity A˜ in MBq·h for each volume, according to equation
(10) and assuming the standard injected activity of 7.4 GBq.
To quantify the absorbed dose to the tumour, the 177Lu S-values associated to each
tumour volume are required. They are easily found in a table of the IDAC spheres mode,
selecting a cumulated activity of 1.0 MBq· h (figure 4.3). A plot of S-values times volume
in mGy·ml/(MBq·h) as a function of volume was created. A logarithmic behaviour was the
most accurate to fit the data. Using the logarithmic equation, it was possible to estimate
the values of S-value of each volume. The correspondent absorbed doses were obtained
with expression (7).
Unfortunately, such small volumes are prone to suffer from PVE during the 68Ga imag-
ing procedure, which results in an underestimation of their radioactivity. Therefore, the
estimated absorbed doses should be corrected taking this fact into account. One way
to perform the correction is employing recovery coefficients characteristic of 68Ga imag-
ing. These coefficients are displayed as a function of the diameter of the objects being
scanned in a paper written by A. Sanchez-Crespo [7]. In view of this, the absorbed doses
PVE corrected can be assessed dividing the doses values already determined by the
correspondent recovery coefficients.
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Figure 4.3: IDAC Dose 2.1. spheres sub-module interface for tumour dosimetry. [20]
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5 Results and discussion
5.1 Biodistribution of [68Ga]SB3
The biodistribution of [68Ga]SB3 within the 10 patients is shown in figure 5.1, along with
the ratio between the administered activity and the body weight in MBq/kg. There is a
strong evidence of a high and homogeneous tracer uptake in the pancreas, in addition
to the excretion of the radiopharmaceutical through the renal pelvis, ureters and urinary
bladder. Patient 7 is not encountered in this representation.
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5.2 Average dosimetry of [68Ga]SB3
Curves of the SUV/BW as a function of time are represented in figure 5.2 for the most
important organs, as well as the tracer uptake in the urine. The estimated TIACs after
integration and their standard error are indicated in 5.1. In table 5.2, organ absorbed
doses and effective doses 60 and 103 are reported for voiding intervals of 0.5h and 1h.
Here, the red bone marrow absorbed dose was estimated with the TIAC obtained from
the PET image data. However, in intermediate calculations, it was noticed that the TIAC
for the red bone marrow was three times higher if estimated from the gamma counter
blood data, which would result in a higher dose to the bone marrow and, consequently, a
higher effective dose. Nevertheless, these changes in dose were not significant, since the
bone marrow is not expected to have a considerable uptake of the radiopharmaceutical,
as seen in the reported biodistribution (figure 5.1).
The organs that receive the highest absorbed dose are the pancreas (198 µGy/MBq),
the kidney pelvis (133 µGy/MBq), the urinary bladder wall (115 µGy/MBq) and the kidney
cortex (53 µGy/MBq) for a 1h voiding interval. Effective dose 60 and 103 values of 15
µSv/MBq and 13 µSv/MBq were obtained, respectively. The reduction of the voiding in-
terval to 30 min produces lower absorbed dose values in following organs: small intestine
wall (-22%), colon wall (-23%), rectum (-43%), prostate (-32%) and urinary bladder wall
(-49%). There is also a decrease in the effective doses 60 (-22%) and 103 (-23%). This
behaviour is expected since these organs are near or belong to the urinary tract and the
radioactivity remains in the urine for a shorter period.
A recent published paper on dosimetry for the bombesin analogue [68Ga]-NODAGA-
M19 shows similar values for the organ absorbed doses and effective dose 103 for a
voiding interval of 1h. Nevertheless, [68Ga]SB3 yields lower absorbed dose in the pan-
creas, liver and spleen, as well as a lower effective dose 103. On the other hand, a
higher absorbed dose is observed in the urinary bladder wall, prostate and kidneys. [28]
Although in the same order of magnitude, the effective dose 103 of [68Ga]SB3 appears
to be slightly lower than the ones reported for the most commonly used radiopharmaceu-
ticals in nuclear medicine diagnostic procedures ([18F]FDG, [68Ga]PSMA, [68Ga]DOTA-
TATE, [68Ga]DOTA-NOC, [68Ga]DOTA-TOC). [2]
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Target organs TIAC (h) Standard Error
Heart wall 6,55E-03 3,65E-03
Red bone marrow3
3,20E-02 7,57E-03
9,45E-02 2,40E-02
Lung 5,89E-03 4,18E-03
Muscle 1,83E-01 6,93E-02
Cortical bone surface 6,55E-03 1,67E-03
Trabecular bone surface 2,91E-03 1,21E-03
Thyroid 3,42E-04 1,36E-04
Liver 4,39E-02 2,15E-02
Spleen 4,37E-03 2,12E-03
Pancreas 7,94E-02 3,35E-02
Pyelum 7,75E-03 1,46E-02
Kidneys 4,82E-02 3,10E-02
Oesophagus 2,35E-06 1,41E-06
Stomach wall 7,00E-06 1,10E-05
Small intestine wall 6,60E-05 2,62E-05
Colon wall 2,15E-05 9,95E-06
Recto-sigmoid colon wall 2,00E-05 9,29E-06
Prostate 1,75E-05 1,57E-05
Urinary bladder contents4
4,45E-04 6,00E-05
1,26E-01 7,78E-02
Table 5.1: TIAC of the targeted organs in h and respective standard error.
3Image and blood sample values.
40.5h and 1h voiding interval.
0.5h voiding 1h voiding
Target organs Dose (mGy/MBq) Dose (mGy/MBq)
Heart wall 7,92E-03 7,94E-03
Red bone marrow 6,73E-03 7,38E-03
Lung 3,21E-03 3,23E-03
Muscle 3,80E-03 4,12E-03
Endosteum 3,72E-03 4,08E-03
Thyroid 6,12E-03 6,12E-03
Liver 1,22E-02 1,22E-02
Spleen 1,04E-02 1,04E-02
Pancreas 1,98E-01 1,98E-01
Pyelum 1,31E-01 1,33E-01
Kidneys 5,24E-02 5,25E-02
Oesophagus 2,20E-03 2,22E-03
Stomach wall 5,03E-03 5,09E-03
Small intestine wall 4,93E-03 6,30E-03
Colon wall 3,37E-03 4,35E-03
Recto-sigmoid colon wall 5,32E-03 9,40E-03
Prostate 2,00E-02 2,92E-02
Urinary bladder wall 5,92E-02 1,15E-01
Effective dose 60 (mSv/MBq) 1,15E-02 1,47E-02
Effective dose 103 (mSv/MBq) 9,95E-03 1,29E-02
Table 5.2: Organs absorbed doses in mGy/MBq and effective doses in mSv/MBq for a 0.5h and 1h voiding
interval, including the image blood values.
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5.3 Individual dosimetry of [68Ga]SB3
Individual TIACs are presented in table 5.3, followed by the respective organ absorbed
doses and effective doses 60 and 103 shown in table 5.4. Average and standard deviation
of these quantities are displayed in 5.5. Since the pancreas behavior did not follow a nor-
mal probability distribution, its statistics was described by the mean, median, maximum
and minimum values in table 5.6. In these results, it is clear the diference in response to
[68Ga]SB3 from patient to patient, despite having been all previously diagnosed with the
same pathology.
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TIAC (h) Dose (mGy/MBq)
Target organs Mean SD Mean SD
Muscle 1,70E-01 4,81E-02 4,29E-03 1,23E-03
Cortical bone surface 3,15E-06 1,40E-06
4,68E-03 1,48E-03
Trabecular bone surface 5,14E-06 2,28E-06
Liver 3,17E-02 1,22E-02 1,39E-02 8,55E-03
Spleen 2,80E-03 1,38E-03 1,02E-02 5,69E-03
Kidneys 1,65E-01 1,46E-01 1,75E-01 1,52E-01
Pyelum 1,34E-02 1,59E-02 2,29E-01 2,61E-01
Stomach wall 3,62E-05 4,31E-05 1,15E-02 1,21E-02
Small intestine wall 2,96E-04 3,10E-04 1,09E-02 7,89E-03
Right colon wall 1,13E-04 1,08E-04
6,94E-03 4,27E-03
Left colon wall 1,06E-04 1,01E-04
Recto-sigmoid colon wall 1,97E-05 5,55E-06 9,07E-03 1,87E-03
Prostate 5,13E-04 2,17E-04 2,93E-02 6,73E-03
Heart 4,34E-03 1,58E-03 6,87E-03 3,28E-03
Lung 3,84E-03 1,76E-03 3,22E-03 1,49E-03
Thyroid 1,49E-03 6,07E-05 4,24E-03 1,22E-03
Oesophagus 1,67E-06 3,83E-07 3,03E-03 1,90E-03
Red bone marrow 3,70E-02 1,91E-02 9,03E-03 3,08E-03
Urinary bladder wall 2,28E-01 5,22E-02 1,07E-01 2,50E-02
Effective dose 60 2,38E-02 2,07E-02
Effective dose 103 2,06E-02 1,24E-02
Table 5.5: Mean and standard deviation of the individual TIAC and absorbed doses.
Mean Median Maximum Minimum
TIAC (h) 2,19E-01 8,82E-02 8,94E-01 3,43E-03
Dose (mGy/MBq) 5,44E-01 2,19E-01 2,21E+00 8,79E-03
Table 5.6: Statistics of the pancreatic TIAC and absorbed dose.
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5.4 Dosimetry estimations for [177Lu]SB3
Estimated absorbed doses for potential organs at risk in a prostate cancer treatment with
[177Lu]SB3 (pancreas, kidneys and red bone marrow) are displayed in table 5.7 for an
injected activity of 7.4 GBq, aside from the results for the intermediate calculations in-
cluding the biologic and effective half-lives of the radiotracer in the target organ and its
TIAC. The highest dose is expected to be achieved in the kidney pelvis, whereas the less
irradiated organ would be the red bone marrow. The pancreas receives less radiation
dose than the one predicted for the bombesin analog [177Lu]-NODAGA-M19. Moreover
and according to the paper published by Gnesin et al, the estimated pancreatic dose
delivered by [177Lu]SB3 will not produce significant toxicity, since the absorbed doses de-
livered in external beam radiotherapy (EBRT), which are at least superior by one order of
magnitude, do not produce harmful effects either. [28] The dose to the bone marrow is
not an issue, since a maximum value of 2 Gy is taken as reference from iodine-131 (131I)
procedings.[30] Regarding the kidney dose, a dose limit of 28 Gy is reported in the euro-
pean guidelines for [177Lu]DOTA-TATE, meaning that the estimated dose for [177Lu]SB3
agrees with this reference level. [2, 31]
The absorbed dose dependence on the pancreas volume is presented in table 5.8,
embracing each pancreas volume along with the average and phantom volumes. The
resulting dose fluctuation (0.7 – 1.6 Gy) is not relevant and similar dose values were
accomplished for the average and phantom volumes, which indicates that the phantom
pancreas is a trustworthy model to predict the pancreatic uptake in this situation.
Predicting the decay of 177Lu from the 68Ga decay comes along with an error, which
is described by an extra dose range in table 5.9. This range quantifies the dose expected
to remain in the organ beyond the scanning time in which the study took place.
Target organs Tbiol (h) Teff (h) TIAC (h) Dose (Gy/GBq)
Dose per 7.4 GBq
injected (Gy)
Pancreas 3,5 3,4 0,3 0,2 1,2
Right kidney 0,2 0,2
1,5 0,3 2,2
Left kidney 0,4 0,4
Pyelum 0,3 0,3 0,6 3,0 22,4
Red bone marrow 0,2 0,2 0,22 0,01 0,06
Table 5.7: Biological half-lives, effective half-lives and TIACs in h, along with doses in Gy/GBq and total
dose estimations in Gy for the organs at risk.
FCUP | 50
Clinical dosimetry and pharmacokinetic modelling of
radiolabeled Sarabesin 3 with 68Ga and 177Lu
Patient number Pancreas volume (ml) Dose per 7.4 GBq injected (Gy)
1 146 0,9
2 114 0,7
3 172 1,1
4 174 1,1
5 144 0,9
6 189 1,2
9 170 1,1
10 247 1,6
11 139 0,9
12 135 0,9
Average 163 1,2
Phantom 174 1,2
Table 5.8: Absorbed dose in Gy for each pancreas volume (per 7.4 GBq of injected activity), including
results for the average and phantom volumes.
Target organs Dose per 7.4 GBq injected (Gy) Extra dose range (Gy)
Pancreas 1,2 0,4 – 3,5
Kidneys 2,2 0,1 – 3,3
Pyelum 22,4 0,0 – 6,8
Red bone marrow 0,1 0,0 – 0,3
Table 5.9: Extra dose range expected in Gy when estimating the decay of 177Lu from the decay of 68Ga.
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5.5 Pharmacokinetics and therapy prediction
The pharmacokinetic analysis of [68Ga]SB3 was performed only for patients 2 and 11,
due to lack of quality in the AIFs obtained for the remaining. The results for the 2-tissue
compartment model fitting are displayed in figures 5.3 and 5.4 for each patient. They
include the AIF and tumour uptake, as well as the model concentration curve (Cmodel),
the concentrations of the tracer in each compartment (C1 and C2), and the model fitted
parameters (K1 to k4).
In PT2 (figure 5.3), the radiotracer presents a fast kinetics, since the specific binding
to the tumour becomes dominant after 36 min (C2 starts exceeding C1). However, C2 de-
creases after 90 min, which suggests that therapy would not be advisable for this patient,
as the specific binding will cease in a much shorter time when comparing to the half-life
of 177Lu. Also, parameters k3 and k4 are similar, which supports this statement.
[68Ga]SB3 shows a slower kinetics in the tumour of PT11 (figure 5.4), as C2 is sig-
nificantly lower than C1 at early time points, which indicates that here the image signal
is mostly due to the perfusion of the tumour than due to specific binding of the tracer.
Specific binding becomes dominant after 170 min, which is more than twice the physi-
cal half-life of 68Ga. This suggests that imaging this tumour with SB3 labelled with 68Ga
might not provide visual information of receptor binding. However, therapy may be a pos-
sibility in this case, since we expect C2 to increase after 170 min and remain high for a
while. Furthermore, the estimated value for k4 is much lower than for k3, which reinforces
the former statement and implies that specific receptor binding is likely to occur within a
period compatible with the half-life of 177Lu.
After selecting PT11 as a possible candidate for therapy, it was evaluated which
model (1- or 2-tissue compartments) described better the pharmacokinetic behaviour
of [68Ga]SB3 in the normal prostate tissue. Figure 5.5 presents concentration curves
of the 2-tissue compartment model applied to the normal prostate, along with the pa-
rameters estimated with both models (1- and 2-tissue compartments). It is clear that
the healthy prostate tissue has very low specific binding, thus it is better described by a
1-tissue compartment model. These results enhance the possibility of an effective ther-
apy with [177Lu]SB3, since having a much higher receptor binding in the tumour than in
normal prostate tissue leads to a higher radiation dose to the tumour cells while sparing
the healthy ones. PT11 expected therapeutic absorbed doses per cycle with [177Lu]SB3
are quantified in table 5.10, for a range of tumour volumes and PVE corrected. It was not
possible to quantify the actual size of the tumour, thus different volumes were considered,
whose upper limit was the phantom prostate volume. Since these volumes were small,
they experience PVE and the absorbed doses need to be corrected with appropriate re-
covery coefficients [7]. The estimated therapeutic doses (PVE corrected) extend from 5.8
Gy to 14.1 Gy, which are significantly higher than the estimated absorbed dose on the
normal prostate (0.1 Gy PVE corrected considering the prostate volume in the phantom).
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(a)
(b)
(c)
Figure 5.3: 2TCM applied in tumour of PT2: (a) Curves of uptake in the blood and tumour together with the
model curve (Cmodel); (b) Model curve (Cmodel) with partial activity concentrations in both compartments
(C1 and C2); (c) Parameters of the model with respective standard error.
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(a)
(b)
(c)
Figure 5.4: 2TCM applied in tumour of PT11: (a) Curves of uptake in the blood and tumour together with
the model curve (Cmodel); (b) Model curve (Cmodel) with partial activity concentrations in both
compartments (C1 and C2); (c) Parameters of the model with respective standard error.
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(a)
(b) (c)
Figure 5.5: Pharmacokinetics of normal prostate of PT11: (a) and (b) show the model curve (Cmodel) with
partial activity concentrations in both compartments (C1 and C2) and the parameters when using a 2TCM;
(c) Parameters when applying a 1TCM.
However, the predicted absorbed doses may not be enough to treat the tumour, since a
radionuclide therapy with [177Lu]PSMA, which is currently under clinical validation, yields
around 97 Gy per 7.4 GBq injected (1 cycle) to treat the tumour. [2]
An attempt to perform pharmacokinetic analysis with PT6 data made us realize the
importance of data quality, mainly regarding the IDIF. Figure 5.6 shows the fitted AIF,
along with the estimated 2TCM parameters for PT6. As can be observed, the data points
are strongly scatted in the peak area, which leads to a poorly fitted AIF. Therefore, the
estimated model parameters are unrealistic, since they suggest that the tracer unbinds
faster than the specific binding occurs (k3 significantly lower than k4) and large stan-
dard errors are associated to those parameters. In the interest of improving data quality
and ensuring that pharmacokinetic modelling is a reasonably accurate method to predict
therapy response of each patient, it is advisable to obtain an AIF based on blood sample
measurements, instead of being image derived.
The interpretation of these results assumes that SB3 remains stable on the blood-
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stream, which was already verified in a previous study. [5] Therefore, metabolyte blood
analysis will not be required for a better estimation, which is an advantage.
Tumour
volume (ml)
Recovery
coefficient
Dose per 7.4 GBq
injected (Gy)
Dose PVE
corrected (Gy)
0,5 0,33 4,7 14,1
1 0,50 4,7 9,4
3 0,69 4,7 6,9
5 0,71 4,8 6,7
7 0,74 4,8 6,4
10 0,78 4,8 6,1
12 0,80 4,8 6,0
14 0,81 4,8 5,9
16 0,82 4,8 5,9
17,8 0,83 4,8 5,8
Table 5.10: Absorbed doses to the tumour of PT11 (with and without PVE correction) depending on tumour
volume and the recovery coefficient.
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Figure 5.6: Scattered AIF of PT6.
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6 Conclusion and future work
The effective dose of [68Ga]SB3 is 13 µSv/MBq, which is similar to the doses of the
most common PET radiopharmaceuticals used at the present time. The organs with the
highest uptake of the radiotracer are the pancreas (198 µGy/MBq), the kidney pelvis (133
µGy/MBq) and the urinary bladder (113 µGy/MBq).
In a therapeutic context, the estimated [177Lu]SB3 absorbed doses for the potential
organs at risk (pancreas, kidneys and red bone marrow) are not expected to produce sig-
nificant toxicity, since agreement with established dose limits was verified. In this group
of patients, the pancreatic absorbed dose did not show a significant dependence on the
pancreas volume and the phantom pancreas demonstrated to be a trustworthy model to
predict the pancreatic uptake. The pancreas volume is considered an important parame-
ter when the therapy provides doses around 40 Gy and the patient has a smaller pancreas
volume than average. However, this is not the case, since the estimated pancreatic dose
is around 5 Gy, which is relatively low.
In the present work, compartmental modelling proved to be a powerful tool to select
the patients for 177Lu therapy based on the 68Ga images, since the activity concentration
in each compartment and rate constants of the models provided valuable information on
the binding properties of the tracer. Therefore, this method offers a possibility to achieve
a personalized medicine approach, discarding the candidates that would not benefit from
this treatment and sparing them from unnecessary radiation exposure.
Patient 2 turned out to be not a good candidate for therapy, as the [68Ga]SB3 specific
binding starts decreasing after 90 min. On the other hand, the kinetic behaviour of the
imaging tracer in the tumour of patient 11 shows that the specific binding gradually in-
creases, becoming dominant after 170 min. From this scenario, it can be stated that this
patient would benefit from the treatment, although the exact behaviour of the [177Lu]SB3
within a week time is not predictable. At this point, estimation of the 177Lu delivered dose
to the tumour would dictate the final decision on the selection for therapy. Unfortunately, a
estimated maximum absorbed dose of 14.1 Gy to the tumour (per cycle) was found, which
may not be enough for its erradication. Two solutions for this issue would be increasing
the number of cycles and/or administrate a higher activity of 177Lu. However, the number
of cycles might be affected by the cumulative dose limit for the organs at risk. Overall,
this analysis also demonstrates the importance of performing pre-treatment dosimetry.
It should be noted that an overall conclusion regarding the possibility of using [177Lu]SB3
as a therapeutic agent for primary stage of prostate cancer was not reached, since it was
only possible to perform the pharmacokinetic analysis based on the imaging data from
two of the patients. However, the results from this work show the potential of the compart-
ment modelling in a particular case and enhance the importance of performing dosimetry
studies before submitting the patients to radionuclide therapy procedures.
Since it was demonstrated that the compartment modelling method depends strongly
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on the quality of AIF, one possible way to reduce the scattering in these curves is to use
an AIF based on blood sample measurements, instead of being image derived. This
modification is expected to optimize the analysis of the data from a certain group of
patients. On the other hand, this solution is not suitable in practice, as it results in a very
painful procedure for the patients.
Over the coming years, the application of [68Ga]SB3 in diagnosing primary prostate
cancer patients, suspected for lymph node metastases, might be evaluated to see if the
lymph node metastases are detected in the images. This might be an alternative diagno-
sis which spares the patients to lymph node dissection and, more importantly, it offers the
possibility of guiding the urologist in deciding whether and where to take tissue punction
samples for pathologic analysis. The same analysis shown in this work might be helpful
in investigating the possibility of employing radionuclide therapy procedures to directly
erradicate the lymph node tumours. Moreover, the same clinical analysis may also be
valuable in assessing the dosimetry and kinetic behaviour of other GRPR antagonists
like NeoBOMB1 and study the possibility of a theranostics approach.[32] At last instance,
the potential of using SB3 for pre- and intra-operative imaging of prostate cancer is cur-
retly under investigation.[33]
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